四环医药重点推荐3-医美行业需求企稳有拐点，预期带动四环新老产品增长 #医美25年获批3大新品全年业绩转正+26年医美加速创新药大幅减亏业绩3倍增长 行业需求： 1）大趋势有企稳迹象：近期调研华东多地反馈经过22-24年客流、零售价格双重承压下，12-1月客流呈现有好转 的态势，美莱、所调研精品机构均实现双位数客流增长。 2）零售价格鉴于人力、营销成本老品逐渐稳定；3）另外老客户 四环医药重点推荐3-医美行业需求企稳有拐点，预期带动四环新老产品增长 4）肉毒是第二大注射品类，目前行业出货量高单位数-低双位数增长，预计未来多年都有增长动能。 四环现有医美核心产品：1）肉毒素乐提葆；2）斯弗妍童颜针倾妍少女针；3）复合动能素冷妍；4）铂安润玻尿 酸；5）黑曜双波黄金微针。 行业需求： 1）大趋势有企稳迹象：近期调研华东多地反馈经过22-24年客流、零售价格双重承压下，12-1月客流呈现有好转 的态势，美莱、所调研精品机构均实现双位数客流增长。 2）零售价格鉴于人力、营销成本老品逐渐稳定；3）另外老客户消费有升级趋势，客单走高。 品类细分： 1）注射填充类玻尿酸有压力，但童颜针2025年因为更多定位中档的厂家获批出 ...

Summary of Conference Call on Medical Aesthetics Industry Industry Overview - The medical aesthetics industry experienced fluctuations in data and trends from the second half of last year to January this year, with overall GMV and revenue slowing down after the second quarter, particularly showing negative growth in the third quarter, but recovering in the fourth quarter [1][2] - The growth in customer traffic is primarily driven by returning customers, with an increase in the proportion of new customers, especially among the younger demographic [2][4] Key Insights - **Revenue Trends**: The industry saw a 5% revenue growth in 2025 compared to 2020, with a 9% increase in customer traffic, although the average transaction value decreased by 4% [3][21] - **Quarterly Performance**: Q4 showed significant revenue growth of 10%, compensating for the low growth in Q2 and Q3, with January's revenue growth exceeding 10% [3][21] - **Customer Composition**: The proportion of returning customers increased from 52% to 58%, with new customer growth driven by new product launches and promotional activities [5][25] - **Product Growth**: New products, particularly botulinum toxin and collagen products, especially recombinant collagen, show growth potential [2][21] Tax Policy Impact - The adjustment of the VAT policy, with medical aesthetics services now subject to a 6% VAT, has impacted industry costs, although institutions are adopting strategies to mitigate this burden [10][28] - The termination of the medical aesthetics tax refund policy in South Korea is expected to benefit the domestic market, as it may encourage consumers to choose local services over traveling abroad [11][29] Product Line Analysis - **Botulinum Toxin Sales**: Sales of botulinum toxin products grew by 25% in 2023 compared to 2022, with a projected growth of 10% in 2025 [6][27] - **Collagen Products**: Sales of collagen products showed varied performance, with some brands experiencing significant growth, such as a 55% increase in sales for certain products in 2025 [12][29] - **Market Acceptance**: New botulinum products are well-received in the market, with institutions willing to adopt them due to their cost-effectiveness and ease of use [8][27] Competitive Landscape - The competition among leading medical aesthetics institutions is intensifying, with varying revenue trends observed among them [4][21] - The market is seeing a trend towards consolidation, with expectations of increased concentration in the industry as smaller institutions may struggle to compete [18][33] Future Outlook - The industry is expected to continue evolving with a focus on light medical aesthetics and increased institutional concentration, prompting companies to adjust their business strategies accordingly [2][21] - The introduction of new products and promotional strategies is anticipated to drive growth, with a target of achieving a 15% growth rate in 2026 [17][31] Additional Considerations - The acceptance and market potential of PDRN salmon needle products are being closely monitored, with expectations for rapid growth following regulatory approvals [14][30] - The overall market dynamics indicate a shift towards more standardized services and data-driven customer management, which may further influence the competitive landscape [33]

Investment Rating - The report maintains a "Buy" rating for the company with a target price of 20.52 CNY, based on a 38x PE ratio for 2025 [3][6]. Core Insights - The company reported a revenue of 49.4 billion CNY for the first three quarters of 2025, reflecting a year-on-year increase of 3.2%, and a net profit attributable to the parent company of 9.8 billion CNY, up 22.4% year-on-year [10]. - The company is expected to benefit from the upcoming release of new products in the medical aesthetics sector, with significant revenue potential from its "童颜针" and "美光针" products [10]. - The report highlights the successful progress in the development of brain-machine interface technology, indicating a substantial market opportunity in the field of neurological diseases [10]. Financial Summary - Revenue projections for 2025-2027 are 6,683 million CNY, 7,424 million CNY, and 8,272 million CNY, respectively, with a year-on-year growth of 9.5%, 11.1%, and 11.4% [5]. - The net profit attributable to the parent company is forecasted to be 1,009 million CNY in 2025, 1,297 million CNY in 2026, and 1,594 million CNY in 2027, with growth rates of 308.6%, 28.6%, and 22.9% respectively [5]. - The gross margin is expected to stabilize around 62.3% in 2025, with net margins projected at 15.1% [5].

Summary of Key Points from Conference Call Records Industry Overview - The conference call primarily discusses the medical aesthetics (医美) industry and related companies, including New Oxygen (新氧), Love Beauty (爱美客), and others in the beauty and healthcare sectors. Core Insights and Arguments 1. **New Oxygen's Business Model**: New Oxygen is leveraging standardized projects and private traffic to reduce costs and attract price-sensitive consumers. However, the increasing demand for high-end projects may raise costs for doctors, posing a challenge for the company's long-term strategy [8][9][11]. 2. **Impact of Market Sentiment**: Runben's stock price rebounded nearly 30% due to market sentiment influenced by the outbreak of diseases in Foshan, despite limited actual sales impact [1][3]. 3. **Acquisition Benefits for Love Beauty**: Love Beauty's acquisition of Region and obtaining the agency rights for Isophane in China has significantly boosted its stock price, with expected profit contributions of over 450 million yuan in the coming year [1][20]. 4. **Challenges for Juzi Biotechnology**: Juzi's sales have declined due to public sentiment issues, leading to a drop in valuation. The recovery of sales through influencer marketing will be crucial for its stock price rebound [1][4][31]. 5. **LePu Medical's Performance**: LePu's main business is affected by centralized procurement, but its medical aesthetics segment is progressing well, with expected revenue contributions from new products [1][13]. 6. **Market Dynamics**: The medical aesthetics industry is experiencing increased competition and price wars, driven by the entry of new products and the need for traditional institutions to adapt to New Oxygen's model [10][12]. Additional Important Insights 1. **Digital Transformation in Beauty Sector**: Companies like Beautiful Farm are enhancing business uniformity and customer acquisition costs through digital systems and training, positioning themselves for growth [2][17]. 2. **Emerging Trends in Marketing**: The rise of short videos and live-streaming as marketing channels is reshaping how brands engage with younger consumers, necessitating innovative strategies [6][8]. 3. **Regulatory Changes**: New regulations on advertising may impact smaller brands more significantly than larger listed companies, potentially improving the competitive landscape for established players [23]. 4. **Future Outlook for Companies**: Companies like Beautiful Farm and Love Beauty are expected to see significant growth due to strategic acquisitions and market positioning, while others like Juzi may need to recover from recent setbacks [17][20][31]. This summary encapsulates the key points discussed in the conference call, highlighting the dynamics within the medical aesthetics industry and the performance outlook for various companies involved.